Literature DB >> 30043140

Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.

Abla Benleulmi-Chaachoua1,2,3, Alan Hegron1,2,3, Marine Le Boulch1,2,3, Angeliki Karamitri1,2,3, Marta Wierzbicka4,5, Victoria Wong4,5, Igor Stagljar4,5, Philippe Delagrange6, Raise Ahmad1,2,3, Ralf Jockers7,8,9.   

Abstract

Melatonin, a neuro-hormone released by the pineal gland, has multiple effects in the central nervous system including the regulation of dopamine (DA) levels, but how melatonin accomplishes this task is not clear. Here, we show that melatonin MT1 and MT2 receptors co-immunoprecipitate with the DA transporter (DAT) in mouse striatal synaptosomes. Increased DA re-uptake and decreased amphetamine-induced locomotor activity were observed in the striatum of mice with targeted deletion of MT1 or MT2 receptors. In vitro experiments confirmed the interactions and recapitulated the inhibitory effect of melatonin receptors on DA re-uptake. Melatonin receptors retained DAT in the endoplasmic reticulum in its immature non-glycosylated form. In conclusion, we reveal one of the first molecular complexes between G protein-coupled receptors (MT1 and MT2) and transporters (DAT) in which melatonin receptors regulate the availability of DAT at the plasma membrane, thus limiting the striatal DA re-uptake capacity in mice.

Entities:  

Keywords:  DAT; Dopamine; Melatonin; Melatonin receptor; Synaptosome

Mesh:

Substances:

Year:  2018        PMID: 30043140     DOI: 10.1007/s00018-018-2876-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  66 in total

1.  Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.

Authors:  Christopher L German; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2012-08-23       Impact factor: 5.372

2.  Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats.

Authors:  Tanawan Leeboonngam; Ratchadaporn Pramong; Kwankanit Sae-Ung; Piyarat Govitrapong; Pansiri Phansuwan-Pujito
Journal:  J Pineal Res       Date:  2017-12-04       Impact factor: 13.007

3.  Behavioural assessment of pinealectomy and foetal pineal gland transplantation in rats: Part II.

Authors:  S Palaoglu; O Palaoglu; E S Akarsu; I H Ayhan; T Ozgen; A Erbengi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons?

Authors:  J Haavik; B Almås; T Flatmark
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

5.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

6.  Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.

Authors:  P Monteleone; M Natale; A La Rocca; M Maj
Journal:  Neuropsychobiology       Date:  1997       Impact factor: 2.328

7.  The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system.

Authors:  Tolga Uz; Ahmet D Arslan; Murat Kurtuncu; Marta Imbesi; Mustafa Akhisaroglu; Yogesh Dwivedi; Ghanshyam N Pandey; Hari Manev
Journal:  Brain Res Mol Brain Res       Date:  2005-05-20

Review 8.  Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges.

Authors:  Jacob Eriksen; Trine Nygaard Jørgensen; Ulrik Gether
Journal:  J Neurochem       Date:  2010-01-18       Impact factor: 5.372

9.  Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.

Authors:  Chun-Hung Lin; Jui-Yen Huang; Cheng-Hsin Ching; Jih-Ing Chuang
Journal:  J Pineal Res       Date:  2008-03       Impact factor: 13.007

10.  Inhibition of dopamine release by melatonin: regional distribution in the rat brain.

Authors:  N Zisapel; Y Egozi; M Laudon
Journal:  Brain Res       Date:  1982-08-19       Impact factor: 3.252

View more
  4 in total

Review 1.  Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry.

Authors:  G Morris; A J Walker; K Walder; M Berk; W Marx; A F Carvalho; M Maes; B K Puri
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

Review 2.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Constitutively active BRS3 is a genuinely orphan GPCR in placental mammals.

Authors:  Huihao Tang; Chuanjun Shu; Haidi Chen; Xiaojing Zhang; Zhuqing Zang; Cheng Deng
Journal:  PLoS Biol       Date:  2019-03-06       Impact factor: 8.029

4.  Identification of Key Regions Mediating Human Melatonin Type 1 Receptor Functional Selectivity Revealed by Natural Variants.

Authors:  Alan Hegron; Eunna Huh; Xavier Deupi; Badr Sokrat; Wenwen Gao; Christian Le Gouill; Mickaël Canouil; Mathilde Boissel; Guillaume Charpentier; Ronan Roussel; Beverley Balkau; Philippe Froguel; Bianca Plouffe; Amélie Bonnefond; Olivier Lichtarge; Ralf Jockers; Michel Bouvier
Journal:  ACS Pharmacol Transl Sci       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.